The recent downward movement has sent Sanofi shares back to attractive levels situated around 82.36 EUR. This zone could put an end to the downward movement and offers a good timing for new long positions. Investors have an opportunity to buy the stock and target the € 88.6.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
In a short-term perspective, the company has interesting fundamentals.
Share prices are approaching a strong support area in daily data, which offers good timing for investors.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The company is in a robust financial situation considering its net cash and margin position.
With a P/E ratio at 13.44 for the current year and 17.42 for next year, earnings multiples are highly attractive compared with competitors.
The company is one of the best yield companies with high dividend expectations.
For the past twelve months, EPS forecast has been revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 78.51 EUR
The company's earnings releases usually do not meet expectations.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.